Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Acute Lymphoblastic Leukemia: early-phase trial registry
58 of 132 indexed Acute Lymphoblastic Leukemia trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #88 of 28,707 conditions by registered trial count.
132 US clinical trials · 58 currently recruiting · #88 of 28,707 conditions by registered trial count
Acute Lymphoblastic Leukemia: 132 US clinical trials tracked, 58 recruiting.
Acute Lymphoblastic Leukemia is the subject of 132 registered US clinical trials on ClinicalTrials.gov, 58 of them currently open to new participants. 8 are in Phase 3-4 (later-stage) and 97 in Phase 1-2 (earlier-stage). The most active sponsor is City of Hope Medical Center, running 15 of these trials.
Enrollment posture brief
Registry condition acute-lymphoblastic-leukemia
OPEN 58 | RECR 44% | LATE 8 | EARLY 97 | RANK #88 | SPON 15
Volume-matched condition peers
Nearest open-share peer: Small Lymphocytic Lymphoma (44% recruiting · 82 trials)
Acute Lymphoblastic Leukemia lists 58 open slots (44% of 132 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Acute Lymphoblastic Leukemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Acute Lymphoblastic Leukemia is recruiting above its size-band peers.
58 of 132 indexed trials (43.9%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Acute Lymphoblastic Leukemia trials is spread across many organizations.
City of Hope Medical Center accounts for 15 of 132 trials (11.4%). 57 distinct sponsors appear on at least one study for this condition label.
-
Most Acute Lymphoblastic Leukemia trials plan to enrol fewer than 100 people.
Median target enrolment is 60 among the 132 trials that report a genuine target (sentinel values excluded). 83 of those (62.9%) plan for fewer than 100 participants.
-
Acute Lymphoblastic Leukemia research is mostly interventional.
116 interventional and 16 observational studies make up this index (87.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
132 total, page 3 of 3
Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant
M.D. Anderson Cancer Center
NCT03622788
Administration of Donor T Cells With the Caspase-9 Suicide Gene
Baylor College of Medicine
NCT01494103
A Study of Venetoclax in Combination With Chemotherapy to Treat Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
Memorial Sloan Kettering Cancer Center
NCT05386576
Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older
Memorial Sloan Kettering Cancer Center
NCT02494882
CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene
Baylor College of Medicine
NCT00710892
Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation
City of Hope Medical Center
NCT04060277
90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome
City of Hope Medical Center
NCT05139004
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Children's Oncology Group
NCT00103285
Cancer Care Delivery in Adolescent and Young Adult Patients With Acute Lymphoblastic Leukemia
Children's Oncology Group
NCT03204916
An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia
Novartis Pharmaceuticals
NCT00171249
Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow
National Heart, Lung, and Blood Institute (NHLBI)
NCT00003838
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
National Cancer Institute (NCI)
NCT02315612
Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy
Notable Labs
NCT04014764
Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.
M.D. Anderson Cancer Center
NCT00390793
Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Amgen Research (Munich)
NCT01471782
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
Fred Hutchinson Cancer Center
NCT00723099
Rapamycin for Immunosuppression and B Cell Modulation Post Stem Cell Transplant for Acute Lymphoblastic Leukemia (ALL)
University of Utah
NCT00795886
ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies
AbbVie (prior sponsor, Abbott)
NCT01110473
Therapeutic Interventions For Pain Induced By Vincristine Treatment For Childhood Acute Lymphoblastic Leukemia (ALL)
St. Jude Children's Research Hospital
NCT01506453
Intensified Post Remission Therapy Containing PEG-Asparaginase
University of Southern California
NCT00184041
T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts
Baylor College of Medicine
NCT00368355
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia
Cellerant Therapeutics
NCT01297543
Improving Blood Stem Cell Collection and Transplant Procedures
National Heart, Lung, and Blood Institute (NHLBI)
NCT01517035
Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT
University of Virginia
NCT04629430
Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation
Dana-Farber Cancer Institute
NCT00144677
Long-Term Follow-up Study for Patients Previously Treated With JCAR015
Juno Therapeutics, a Subsidiary of Celgene
NCT02813252
Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia
H. Lee Moffitt Cancer Center and Research Institute
NCT03575325
Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant
Andrew Rezvani
NCT03267186
CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML
Robert Lowsky
NCT04151706
A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT01184885
Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia
OHSU Knight Cancer Institute
NCT02779283
TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia
TCR2 Therapeutics
NCT04323657
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 49 |
| Phase 2 | 48 |
| Phase 3 | 7 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Acute Lymphoblastic Leukemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Acute Lymphoblastic Leukemia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Acute Lymphoblastic Leukemia page
132 registered trials, 58 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 58 Acute Lymphoblastic Leukemia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- City of Hope Medical Center sponsors the most Acute Lymphoblastic Leukemia trials on record, review their full trial history before evaluating a specific study. See City of Hope Medical Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Acute Lymphoblastic Leukemia condition card totals 132 registered trials; most-linked intervention Cyclophosphamide; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.